Public Company Edition: BioAge will fund a Phase II trial of its muscle atrophy prevention drug in combination with an obesity drug with its initial public offering proceeds. Also, Ascendis and Wave raised $281.3m and $200m, respectively, after positive clinical trial readouts.

The Danish company released pivotal data for TransCon CNP in children with achondroplasia that appears competitive with BioMarin’s big growth driver.

ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering. Also, Circle Pharma closed a $90m series D round and Jazz priced an $850m note sale, but IN8bio revealed a prioritization plan and job cuts.

The company laid out a growth strategy to investors centered on three business units, $4bn in revenue by 2027 and $500m in cost savings.